The British Journal of Clinical Pharmacy
— Volume 1, Issue 9, October 2009
To download the complete issue, please select one of the following formats:
              
oct09_cover.jpg
Tocilizumab (RoActemra; Roche) was launched in the UK this month for the treatment of rheumatoid arthritis. Although preliminary recommendations by NICE do not look promising, pharmacists should understand its use and practical implications. By Richard Copeland.
An increasing number of patients are undergoing interventional procedures for cardiac rhythm irregularities. This case study describes the pharmacological management of a patient undergoing ablation therapy for atrial fibrillation. By Gurpreet Virdi and Sotiris Antoniou.
Tocilizumab is an interleukin-6 receptor inhibitor that was launched this month for moderate to severe rheumatoid arthritis. In this article, the North Central London Formulary and Medicines Management Groups review the evidence for its efficacy and safety. By Anthony Grosso and Pritesh Bodalia.
Prescriber’s Corner describes situations encountered by pharmacist prescribers and invites you to consider clinical decisions about the patient. In this case, you are undertaking a routine medicines use review when you notice an abnormality in thyroid levels. By Andrew Husband and John Sherwood.
Linda Matthew is the interim head of Patient Safety Direct, part of the National Reporting and Learning Service at the National Patient Safety Agency.  This article describes Ms Matthew’s role at the NPSA and how her work contributes to improving patient safety. By Shona Kirk.
Following the publication of medicines adherence guidance by the National Institute for Health and Clinical Excellence earlier this year, Nina Barnett and Lelly Oboh outline the key principles for pharmacists and give examples of putting them into practice.
Generic substitution by pharmacists is expected to be introduced next year. However, prescribing generic medicines solely on the basis of cost would risk lowering standards in safety and quality, says Philip Brown.